Helicobacter pylori eradication and the prevention of peptic ulcer bleeding and cardiovascular disease progression in chronic aspirin users

Table 3 Prevalence of cardiovascular diseases in study participants before Helicobacter pylori treatment, n (%)

Disease	H. pylori positive	H. pylori negative	P value
IHD	142 (54.3)	46 (33.3)	< 0.001
PCI	23 (8.7)	17 (12.5)	0.012
IHD-PCI	17 (6.5)	17 (12.5)	0.018
CABG	46 (17.4)	17 (12.5)	0.045
CSA	6 (2.1)	0 (0.0)	0.078
Post CABG	11 (4.2)	17 (12.5)	0.064
Post PCI	6 (2.1)	0 (0.0)	0.210
Inferior MI	6 (2.1)	6 (4.2)	0.320
Prosthetic MV	6 (2.1)	6 (4.2)	0.320
Post PCS	6 (2.1)	0 (0.0)	0.210

Comparisons between groups were performed using the χ² test. A P value < 0.05 was considered statistically significant. IHD: Ischemic heart disease; CSA: Chronic stable angina; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass graft; MI: Myocardial infarction; MV: Mitral valve; PCS: Post-cardiac surgery; H. pylori: Helicobacter pylori.